increxxa
elanco gmbh - tulatromysiini - systeemiseen käyttöön tarkoitetut antibakteerit - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. the product should only be used if pigs are expected to develop the disease within 2–3 days. lampaat: tarttuvan pododermatiitin (jalkajuhla) alkuvaiheen hoito, johon liittyy virulentti dichelobacter nodosus, joka vaatii systeemistä hoitoa.
sugammadex orion 100 mg/ml injektioneste, liuos
orion corporation orion pharma - sugammadex sodium - injektioneste, liuos - 100 mg/ml - sugammadeksi
enalapril orion 5 mg tabletti
orion corporation - enalapril maleate - tabletti - 5 mg - enalapriili
enalapril orion 10 mg tabletti
orion corporation - enalapril maleate - tabletti - 10 mg - enalapriili
enalapril orion 20 mg tabletti
orion corporation - enalapril maleate - tabletti - 20 mg - enalapriili
rapilysin
actavis group ptc ehf - reteplaasia - sydäninfarkti - antitromboottiset aineet - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
zinforo
pfizer ireland pharmaceuticals - keftaroliinifosamiili - community-acquired infections; skin diseases, infectious; pneumonia - systeemiset bakteerilääkkeet, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
ketipinor 50 mg depottabletti
orion corporation - quetiapine fumarate - depottabletti - 50 mg - ketiapiini
ketipinor 150 mg depottabletti
orion corporation - quetiapine fumarate - depottabletti - 150 mg - ketiapiini
ketipinor 200 mg depottabletti
orion corporation - quetiapine fumarate - depottabletti - 200 mg - ketiapiini